Skip to main content
Sign In

Hugo R. Rosen, MD, FACP

Waterman Professor of Medicine and Immunology Head, Division of Gastroenterology & Hepatology


Hugo R. Rosen, MD, FACP
Waterman Professor of Medicine and Immunology
Head, Division of Gastroenterology & Hepatology


  • Medical School: University of Miami School of Medicine, 1989
  • Internship/Residency: Beth Israel Deaconess Medical Center, 1989-1992
  • Fellowship: University of California, Los Angeles, 1992-1995
  • Board Certified in Internal Medicine, Gastroenterology (2025), and Transplant Hepatology (2012)

Honors and Awards

  • University of Miami Presidential Academic Scholarship
  • NIH training grant (UCLA)
  • Senator Mark Hatfield Award for Clinical Research
  • American Society of Transplantation Award for Research Excellence in Clinical Science (two times)
  • Guest Editor, Clinics in Liver Disease (four times)
  • Merit Review Award (three times)
  • American Society for Clinical Investigation (ASCI)

Faculty Appointments

  • Portland VA Medical Center
  • Oregon Health & Sciences University, 1995-2005
  • Associate Professor of Medicine, Molecular Biology, and Immunology, 2000-2005
  • Professor of Medicine and Head, Division of Gastroenterology & Hepatology, University of Colorado, July, 2005 - present

Committees and Responsibilities

  • Deputy Editor, Hepatology (2016-2022)
  • Director, NIH-sponsored Hepatitis C Center Grant
  • Member, NIH Hepatobiliary Study Section
  • Executive Planning Committee, American Society Transplantation
  • Associate Editor, Liver Transplantation (2005-2015)
  • Board of Directors, American Society Transplantation
  • Board of Directors, Clinical Care Options
  • NIH Action Plan in Liver Disease
  • Chairman, Liver and Intra-abdominal Organs, American Society of Transplant Physicians (developed guidelines for transplant hepatology training)

Clinical Interests:

Hepatitis C, general hepatology and liver transplantation

Research Interests

The focus of our laboratory is to understand the immune response to hepatitis C virus (HCV), particularly the mechanisms associated with spontaneous or therapeutic clearance versus viral persistence. The balance between HCV and host immune response depends on multiple factors such as nature of the infecting virus, route of infection and initial viral burden, genetic background of the individual as well as the immune status of the infected host. The interplay between these parameters ultimately determines the spectrum of possible clinical outcomes associated with viral infection. We currently have federally funded research programs, including a recently awarded NIH HCV Center grant.

Representative Publications (from >200)

  1. Rosen HR.  Emerging concepts in immunity to hepatitis C virus infection.  J Clinical Investigation 2013; 123 (10):  4121-4130.    PMID:  24084744​

  2. Giugliano S, Kriss M, Golden-Mason L, Lemon S, Shaw G, Shah V, Rosen HR.   Hepatitis C Virus Infection Induces Autocrine Interferon Signaling by Human Liver Endothelial Cell and Release of Exosomes, Which Inhibits Viral Replication.  Gastroenterology 2015 Feb;148(2):392-402 (see editorial).  

  3. Giugliano S, Petroff MG, Warren BD, Jasti S, Linscheid C, Ward A, Kramer A, Dobrinskikh E, Sheiko MA, Gale M Jr, Golden-Mason L, Winn VD, Rosen HRHepatitis C Virus Sensing by Human Trophoblasts Induces Innate Immune Responses and Recruitment of Maternal NK Cells: Potential Implications for Limiting Vertical Transmission. J Immunol. 2015 Oct 15;195(8):3737-47.

  4. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile Acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic Fatty liver disease. J Biol Chem. 2013 Apr 26;288(17):11761-70.​

  5. Rosen HR. Chronic hepatitic C infection. N Engl J Med. 2011 Jun 23;364(25):2429-38. (Chronic Hepatits C Infection.pdfChronic Hepatits C Infection.pdf)

  6. Hurtado CW, Golden-Mason L, Brocato M, Krull M, Narkewicz MR, Rosen HR. Innate immune function in placenta and cord blood of hepatitis C - seropositive mother-infact dyads. PLoS One. 2010 Aug 30;5(8):e12232. (Innate Immune Function.pdfInnate Immune Function.pdf)

  7. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased nature killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.  Hepatology. 2010 Nov;52(5):1581-9. (Increased Natural Killer.pdfIncreased Natural Killer.pdf)

  8. Mengshol JA, Golden-Mason L, Arikawa T, Smith M, Niki T, McWilliams R, Randall JA, McMahan R, Zimmerman MA, Rangachari M, Dobrinskikh E, Busson P, Polyak SJ, Hirashima M, Rosen HR. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One. 2010 Mar 4;5(3):e9504. (A Crucial Role.pdfA Crucial Role.pdf)

  9. Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology. 2008 May; 134(6):1789-801. Review. (Transplantation Immunology.pdfTransplantation Immunology.pdf)

  10. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR. Upregulation of PD-1 expression on circulating and intrahepatic HCV- specific CD8+ T cells associated with reversible immune dysfunction. J Virol. 2007 June 13; [Epub ahead of print]

  11. Golden-Mason L, Castelblanco N, O’Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos NT cells determine outcome of acute HCV infection. J Virol. 2007 Jun 6; [Epub ahead of print]

  12. Wertheimer AM, Polyak SJ, Leistikow R, Rosen HR. Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology 2007 Jun;45(6):1422-32.

  13. Golden-Mason L, Burton JR Jr., Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006 Nov;44(5):1098-109.

  14. Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis 2006 Aug; 15;194(4):454-63.

  15. Smyk-Pearson S, Tester IA, Palmer B, Golden-Mason L, Klarquist J, Rosen HR. Spontaneous recovery in acute human HCV infection: functional T-cell thresholds and relative importance of CD4 help. J. of Virology. 2008: 82(4):1827-1837. (download PDF)

  16. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol. 2007; 4(11):622-634. (download PDF)

  17. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008; 180(6):3637-3641. (download PDF)

  18. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transplantation. 2008; 14(1):31-40. (download PDF)

  19. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med. 2005 Jun 6;201(11):1725-31 (see comments). (download PDF)

  20. Weston S, Leistikow, Reddy R, Wertheimer AM, Lewinsohn DM, Chou S, Corless CL, O'Farrelly C, Nelson D, Rosen HR. Reconstitution of hepatitis C virus-specific T cell-mediated immunity following liver transplantation. Hepatology 2005 Jan;41(1):72-81. (download PDF)